论文部分内容阅读
Zardaverine 为磷酸二酯酶(PDE)Ⅲ和Ⅳ的抑制剂。吸入后,可致哮喘患者急性支气管舒张。患者和方法临床稳定期支气管哮喘患者12例(女3例),年龄21～54岁,有轻至中度可逆性支气管阻塞(FEV_1占预计值的50%～85%),吸入舒喘灵200μg 后FEV_1增加15%～36%。首次就诊时进行常规肺功能检查及支气管阻塞可逆性检测。第2次和第3次随访(每次间隔1周)时,以交叉、随机及双盲的方式给患者定量吸入Zardaverine(1.5mg/喷)或安慰剂,共4次,每喷间隔15min。于每喷吸入后5min 时
Zardaverine is an inhibitor of phosphodiesterase (PDE) III and IV. Inhalation, can cause acute bronchial asthma in patients with diastolic. Patients and Methods Clinical stable bronchial asthma in 12 patients (3 females), aged 21 to 54 years old, mild to moderate reversible bronchial obstruction (FEV_ accounted for 50% to 85% of the expected value), inhaled salbutamol 200μg After FEV_1 increased by 15% to 36%. The first visit to carry out routine pulmonary function tests and bronchial obstruction reversibility test. Patients were dosed with Zardaverine (1.5 mg / spray) or placebo in a crossover, randomized, and double-blind manner on 4 and 3 occasions at intervals of 15 min between Visit 2 and Visit 3 at 1 week intervals. 5min after each spray inhalation